{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T21:29:11Z","timestamp":1788125351086,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Different surgical options existed in the management of axilla among breast cancer patients who were initially node-positive and were converted node-negative after neoadjuvant systemic treatment (NST). De-escalation of axillary surgery was feasible, but previous studies focused on the false-negative rate (FNR) of respective procedures. The aim of this study is to evaluate the oncological outcomes of sentinel lymph-node biopsy (SLNB), MARI procedure, and targeted axillary dissection (TAD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>PubMed, Embase, and the Cochrane library literature databases were searched systematically. Studies were eligible if they addressed the axillary recurrence rate of patients with nodal pathological complete response (pCR) and omission of axillary lymph-node dissection (ALND) after NST. Pooled analysis was performed using inverse variance methods for logit transformed proportions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eleven retrospective studies and three prospective studies involving 4268 patients with node-positive breast cancers were included. A total of 1650 patients achieved nodal pCR and avoided ALND, 1382 patients with SLNB only and 268 patients with MARI\/TAD. The pooled estimate of axillary recurrence was 2.1% (95%CI 1.4\u20133.2%) for patients with negative SLNB and 1.5% (95% CI 0.5\u20134.1%) for patients with negative MARI\/TAD. There was no significant benefit of ALND over SLNB in patients with nodal pCR after NST. Pooled estimates of 5-year DFS, DDFS, and OS of SLNB alone were 0.87 (95% CI 0.83\u20130.90], 0.90 (95% CI 0.88\u20130.92), and 0.92 (95% CI 0.88\u20130.94), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Breast cancer patients who are converted node-negative after NST have extremely low nodal recurrence rate, irrespective of the choice of axillary surgery. Omission of ALND is oncologically safe in patients who have nodal pCR after NST.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12282-025-01692-9","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:45:11Z","timestamp":1743893111000},"page":"638-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Different strategies in de-escalation of axillary surgery in node-positive breast cancer following neoadjuvant treatment: a systematic review and meta-analysis of long-term outcomes"],"prefix":"10.1007","volume":"32","author":[{"given":"Vivian","family":"Man","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Pan","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Hiu","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-9489","authenticated-orcid":false,"given":"Ava","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"issue":"3","key":"1692_CR1","first-page":"251","volume":"23","author":"VC Man","year":"2017","unstructured":"Man VC, Cheung PS. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer. Hong Kong Med J. 2017;23(3):251\u20137.","journal-title":"Hong Kong Med J"},{"key":"1692_CR2","doi-asserted-by":"publisher","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8. Erratum in: Lancet. 2019;393(10175):986.","DOI":"10.1016\/S0140-6736(13)62422-8"},{"issue":"15","key":"1692_CR3","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804. https:\/\/doi.org\/10.1200\/JCO.2011.38.8595.","journal-title":"J Clin Oncol."},{"key":"1692_CR4","doi-asserted-by":"publisher","unstructured":"Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608\u201314; discussion 614\u20136. https:\/\/doi.org\/10.1097\/SLA.0000000000000924.","DOI":"10.1097\/SLA.0000000000000924"},{"key":"1692_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncology. 2013;14:609\u201318.","journal-title":"Lancet Oncology"},{"key":"1692_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study. J Clin Oncol. 2015;33:258\u201364.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1692_CR7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","volume":"263","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Feliberti EC, Hunt KK. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0\u2013T4, N1\u2013N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000001375.","journal-title":"Ann Surg"},{"issue":"2","key":"1692_CR8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","volume":"261","author":"M Donker","year":"2015","unstructured":"Donker M, Straver ME, Wesseling J, Loo CE, Schot M, Drukker CA, et al. Marking axillary lymph node with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378\u201382.","journal-title":"Ann Surg"},{"key":"1692_CR9","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1692_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/bjs\/znac217","volume":"109","author":"ML Gasparri","year":"2022","unstructured":"Gasparri ML, de Boniface J, Poortmans P, Gentilini OD, Kaidar-Person O, Banys-Paluchowski M, et al. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. Br J Surg. 2022;109(9):857\u201363. https:\/\/doi.org\/10.1093\/bjs\/znac217.","journal-title":"Br J Surg"},{"key":"1692_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.breast.2022.12.010","volume":"67","author":"V Galimberti","year":"2023","unstructured":"Galimberti V, Ribeiro Fontana SK, Vicini E, Morigi C, Sargenti M, Corso G, et al. This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients. Breast. 2023;67:21\u20135. https:\/\/doi.org\/10.1016\/j.breast.2022.12.010.","journal-title":"Breast."},{"issue":"3","key":"1692_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/bjs\/znac413","volume":"110","author":"S Keelan","year":"2023","unstructured":"Keelan S, Boland MR, Ryan \u00c9J, Moran LR, Davey MG, Lloyd AJ, et al. Long-term survival in patients with node-positive breast cancer who undergo sentinel lymph node biopsy alone after neoadjuvant chemotherapy: meta-analysis. Br J Surg. 2023;110(3):324\u201332. https:\/\/doi.org\/10.1093\/bjs\/znac413.","journal-title":"Br J Surg"},{"issue":"9","key":"1692_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"1692_CR14","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1245\/s10434-018-6637-9","volume":"25","author":"TT Nguyen","year":"2018","unstructured":"Nguyen TT, Hoskin TL, Day CN, Degnim AC, Jakub JW, Hieken TJ, et al. Decreasing use of axillary dissection in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(9):2596\u2013602. https:\/\/doi.org\/10.1245\/s10434-018-6637-9.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1692_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4048\/jbc.2015.18.1.22","volume":"18","author":"JY Kim","year":"2015","unstructured":"Kim JY, Kim MK, Lee JE, Jung Y, Bae SY, Lee SK, et al. Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with initial cytology-proven axillary node metastasis. J Breast Cancer. 2015;18(1):22\u20138. https:\/\/doi.org\/10.4048\/jbc.2015.18.1.22.","journal-title":"J Breast Cancer."},{"issue":"1","key":"1692_CR16","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.clbc.2016.06.020","volume":"17","author":"S Park","year":"2017","unstructured":"Park S, Lee JE, Paik HJ, Ryu JM, Bae SY, Lee SK, et al. Feasibility and prognostic effect of sentinel lymph node biopsy after neoadjuvant chemotherapy in cytology-proven. Node-Positive Breast Cancer Clin Breast Cancer. 2017;17(1):e19\u201329. https:\/\/doi.org\/10.1016\/j.clbc.2016.06.020.","journal-title":"Node-Positive Breast Cancer Clin Breast Cancer"},{"issue":"2","key":"1692_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10549-017-4423-1","volume":"166","author":"YJ Kang","year":"2017","unstructured":"Kang YJ, Han W, Park S, You JY, Yi HW, Park S, et al. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2017;166(2):473\u201380. https:\/\/doi.org\/10.1007\/s10549-017-4423-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1692_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","volume":"42","author":"V Galimberti","year":"2016","unstructured":"Galimberti V, Ribeiro Fontana SK, Maisonneuve P, Steccanella F, Vento AR, Intra M, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol. 2016;42(3):361\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2015.11.019.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"1692_CR19","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1097\/SLA.0000000000004562","volume":"276","author":"G Martelli","year":"2022","unstructured":"Martelli G, Barretta F, Miceli R, Folli S, Maugeri I, Listorti C, et al. Sentinel node biopsy alone or with axillary dissection in breast cancer patients after primary chemotherapy: long-term results of a prospective interventional study. Ann Surg. 2022;276(5):e544\u201352. https:\/\/doi.org\/10.1097\/SLA.0000000000004562.","journal-title":"Ann Surg"},{"issue":"12","key":"1692_CR20","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","volume":"7","author":"AV Barrio","year":"2021","unstructured":"Barrio AV, Montagna G, Mamtani A, Sevilimedu V, Edelweiss M, Capko D, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event. JAMA Oncol. 2021;7(12):1851\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4394.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1692_CR21","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1016\/j.ejso.2021.06.024","volume":"47","author":"N Cab\u0131o\u011flu","year":"2021","unstructured":"Cab\u0131o\u011flu N, Karanl\u0131k H, Y\u0131ld\u0131r\u0131m N, M\u00fcsl\u00fcmano\u011flu M, \u00c7akmak Karadeniz G, Trabulus Can D, et al. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node-positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study. Eur J Surg Oncol. 2021;47(10):2506\u201314. https:\/\/doi.org\/10.1016\/j.ejso.2021.06.024.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"1692_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/jpm11030172","volume":"11","author":"AM Sanchez","year":"2021","unstructured":"Sanchez AM, Terribile D, Franco A, Martullo A, Orlandi A, Magno S, et al. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: preliminary experience with clinically node negative patients after systemic treatment. J Pers Med. 2021;11(3):172. https:\/\/doi.org\/10.3390\/jpm11030172.","journal-title":"J Pers Med"},{"issue":"4","key":"1692_CR23","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, Vicini E, Morigi C, Corso G, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol. 2021;47(4):804\u201312. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"1692_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251597","volume":"16","author":"SB Lee","year":"2021","unstructured":"Lee SB, Kim H, Kim J, Chung IY, Kim HJ, Ko BS, et al. Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy. PLoS One. 2021;16(5): e0251597. https:\/\/doi.org\/10.1371\/journal.pone.0251597.","journal-title":"PLoS One"},{"issue":"6","key":"1692_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4048\/jbc.2021.24.e48","volume":"24","author":"H Kim","year":"2021","unstructured":"Kim H, Han J, Kim SY, Lee ES, Kang HS, Lee S, et al. Sentinel lymph node biopsy in breast cancer patients with pathological complete response in the axillary lymph node after neoadjuvant chemotherapy. J Breast Cancer. 2021;24(6):531\u201341. https:\/\/doi.org\/10.4048\/jbc.2021.24.e48.","journal-title":"J Breast Cancer"},{"issue":"2","key":"1692_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10549-020-06011-8","volume":"186","author":"AP Damin","year":"2021","unstructured":"Damin AP, Zancan M, Melo MP, Biazus JV. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach. Breast Cancer Res Treat. 2021;186(2):527\u201334. https:\/\/doi.org\/10.1007\/s10549-020-06011-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1692_CR27","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1245\/s10434-020-09211-0","volume":"28","author":"SM Wong","year":"2021","unstructured":"Wong SM, Basik M, Florianova L, Margolese R, Dumitra S, Muanza T, et al. Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2021;28(5):2621\u20139. https:\/\/doi.org\/10.1245\/s10434-020-09211-0.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1692_CR28","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","volume":"27","author":"MA Piltin","year":"2020","unstructured":"Piltin MA, Hoskin TL, Day CN, Davis J Jr, Boughey JC. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2020;27(12):4795\u2013801. https:\/\/doi.org\/10.1245\/s10434-020-08900-0.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1692_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4048\/jbc.2018.21.e54","volume":"21","author":"HJ Choi","year":"2018","unstructured":"Choi HJ, Kim I, Alsharif E, Park S, Kim JM, Ryu JM, et al. Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with axillary node-positive breast cancer in diagnosis. J Breast Cancer. 2018;21(4):433\u201341. https:\/\/doi.org\/10.4048\/jbc.2018.21.e54.","journal-title":"J Breast Cancer."},{"issue":"1","key":"1692_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-022-06545-z","volume":"193","author":"AA van Loevezijn","year":"2022","unstructured":"van Loevezijn AA, van der Noordaa MEM, Stokkel MPM, van Werkhoven ED, Groen EJ, Loo CE, et al. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol. Breast Cancer Res Treat. 2022;193(1):37\u201348. https:\/\/doi.org\/10.1007\/s10549-022-06545-z.","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"1692_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamasurg.2023.1772","volume":"158","author":"S Kuemmel","year":"2023","unstructured":"Kuemmel S, Heil J, Bruzas S, Breit E, Schindowski D, Harrach H, et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023;158(8):807\u201315. https:\/\/doi.org\/10.1001\/jamasurg.2023.1772.","journal-title":"JAMA Surg"},{"issue":"7","key":"1692_CR32","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1097\/JS9.0000000000000331","volume":"109","author":"SY Wu","year":"2023","unstructured":"Wu SY, Li JW, Wang YJ, Jin KR, Yang BL, Li JJ, et al. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study. Int J Surg. 2023;109(7):1863\u201370. https:\/\/doi.org\/10.1097\/JS9.0000000000000331.","journal-title":"Int J Surg"},{"issue":"9","key":"1692_CR33","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med."},{"issue":"9","key":"1692_CR34","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdt182.","journal-title":"Ann Oncol"},{"key":"1692_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.breast.2023.06.011","volume":"71","author":"AKE van Hemert","year":"2023","unstructured":"van Hemert AKE, van Duijnhoven FH, Vrancken Peeters MTFD. This house believes that: MARI\/TAD is better than sentinel node biopsy after PST for cN+ patients. Breast. 2023;71:89\u201395. https:\/\/doi.org\/10.1016\/j.breast.2023.06.011.","journal-title":"Breast."},{"issue":"6","key":"1692_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","volume":"10","author":"G Montagna","year":"2024","unstructured":"Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10(6):793\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0578.","journal-title":"JAMA Oncol"},{"key":"1692_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07104-w","author":"SZ Lim","year":"2023","unstructured":"Lim SZ, Yoo TK, Lee SB, Kim J, Chung IY, Ko BS, et al. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2023. https:\/\/doi.org\/10.1007\/s10549-023-07104-w.","journal-title":"Breast Cancer Res Treat."},{"issue":"7","key":"1692_CR38","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1245\/s10434-024-15292-y","volume":"31","author":"A Pfob","year":"2024","unstructured":"Pfob A, Kokh DB, Surovtsova I, Riedel F, Morakis P, Heil J. Oncologic outcomes for different axillary staging techniques in patients with nodal-positive breast cancer undergoing neoadjuvant systematic treatment: a cancer registry study. Ann Surg Oncol. 2024;31(7):4381\u201392. https:\/\/doi.org\/10.1245\/s10434-024-15292-y.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1692_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/tbj.14206","volume":"27","author":"NE Sharp","year":"2021","unstructured":"Sharp NE, Sachs DB, Melchior NM, Albaneze P, Nardello S, Sigurdson ER, et al. Does the false-negative rate for 1 or 2 negative sentinel nodes after neoadjuvant chemotherapy translate into a high local recurrence rate? Breast J. 2021;27(4):335\u201344. https:\/\/doi.org\/10.1111\/tbj.14206.","journal-title":"Breast J."},{"issue":"2","key":"1692_CR40","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00268-017-4171-8","volume":"42","author":"EY Kim","year":"2018","unstructured":"Kim EY, Byon WS, Lee KH, Yun JS, Park YL, Park CH, et al. Feasibility of preoperative axillary lymph node marking with a clip in breast cancer patients before neoadjuvant chemotherapy: a preliminary study. World J Surg. 2018;42(2):582\u20139.","journal-title":"World J Surg"},{"issue":"11","key":"1692_CR41","doi-asserted-by":"publisher","first-page":"e1621","DOI":"10.1634\/theoncologist.2020-0494","volume":"25","author":"GH Lim","year":"2020","unstructured":"Lim GH, Gudi M, Teo SY, Ng RP, Yan Z, Lee YS, et al. Would removal of all ultrasound abnormal metastatic lymph nodes without sentinel lymph node biopsy be accurate in patients with breast cancer with neoadjuvant chemotherapy? Oncologist. 2020;25(11):e1621\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2020-0494.","journal-title":"Oncologist."},{"issue":"11","key":"1692_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/jamasurg.2022.3907","volume":"157","author":"JM Simons","year":"2022","unstructured":"Simons JM, van Nijnatten TJA, van der Pol CC, van Diest PJ, Jager A, van Klaveren D, et al. Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. JAMA Surg. 2022;157(11):991\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2022.3907.","journal-title":"JAMA Surg"},{"issue":"5","key":"1692_CR43","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1097\/SLA.0000000000004572","volume":"276","author":"S Kuemmel","year":"2022","unstructured":"Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of Targeted Axillary Dissection (TAD) in node-positive breast cancer patients. Ann Surg. 2022;276(5):e553\u201362. https:\/\/doi.org\/10.1097\/SLA.0000000000004572.","journal-title":"Ann Surg"},{"key":"1692_CR44","doi-asserted-by":"publisher","unstructured":"Friedrich M, K\u00fchn T, Janni W, M\u00fcller V, Banys-Pachulowski M, Kolberg-Liedtke C, et al. AGO recommendations for the surgical therapy of the axilla after neoadjuvant chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd. 2021;81(10):1112\u20131120. https:\/\/doi.org\/10.1055\/a-1499-8431. Epub 2021 Oct 6. Erratum in: Geburtshilfe Frauenheilkd. 2021;81(10):e31","DOI":"10.1055\/a-1499-8431"},{"issue":"6","key":"1692_CR45","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(6):691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030.","journal-title":"J Natl Compr Canc Netw."},{"issue":"4","key":"1692_CR46","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","volume":"273","author":"S Samiei","year":"2021","unstructured":"Samiei S, de Mooij CM, Lobbes MBI, Keymeulen KBMI, van Nijnatten TJA, Smidt ML. Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2021;273(4):694\u2013700. https:\/\/doi.org\/10.1097\/SLA.0000000000004356.","journal-title":"Ann Surg"},{"issue":"6","key":"1692_CR47","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375. https:\/\/doi.org\/10.1001\/jama.2011.90.","journal-title":"JAMA"},{"issue":"12","key":"1692_CR48","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol."},{"issue":"2","key":"1692_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.clbc.2021.06.003","volume":"22","author":"A Schlafstein","year":"2022","unstructured":"Schlafstein A, Liu Y, Goyal S, Kahn S, Godette K, Lin J, et al. Regional nodal irradiation for clinically node-positive breast cancer patients with pathologic negative nodes after neoadjuvant chemotherapy. Clin Breast Cancer. 2022;22(2):127\u201335. https:\/\/doi.org\/10.1016\/j.clbc.2021.06.003.","journal-title":"Clin Breast Cancer"},{"key":"1692_CR50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ctro.2022.11.014","volume":"38","author":"JK Kim","year":"2022","unstructured":"Kim JK, Karp JM, Gerber NK. Regional nodal irradiation (RNI) in breast cancer patients with residual isolated tumor cells or micrometastatic nodal disease after neoadjuvant chemotherapy. Clin Transl Radiat Oncol. 2022;38:195\u2013201. https:\/\/doi.org\/10.1016\/j.ctro.2022.11.014.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1692_CR51","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01872975 - accessed January 2024"},{"issue":"4","key":"1692_CR52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health."},{"issue":"7","key":"1692_CR53","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.3390\/cancers13071565","volume":"13","author":"M Banys-Paluchowski","year":"2021","unstructured":"Banys-Paluchowski M, Gasparri ML, de Boniface J, Gentilini O, Stickeler E, Hartmann S, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers (Basel). 2021;13(7):1565.","journal-title":"Cancers (Basel)"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01692-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01692-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01692-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:44:40Z","timestamp":1750164280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01692-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01692-9","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no funding for this study and there is no conflict of interest for disclosure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}